ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic

ProBioGen and Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, announced the successful completion of a sprint project to deliver clinical material. The partnership focused on an integrated and accelerated chemistry, manufacturing, and controls (CMC) program for MAR002, Marea's investigational anti-growth hormone receptor (GHR) antibody for the treatment of acromegaly, encompassing cell line development, process development, formulation development, and GMP manufacturing services.

The collaboration first leveraged ProBioGen's CHO.RiGHT® cell line development platform, including its proprietary DirectedLuck® transposase technology, to generate superior, high-yielding clone pools for early material production for IND-enabling toxicology studies. Additionally, the stable platform enabled the development of a robust, scalable manufacturing process, including integrated, seamless drug product (DP) manufacturing at Marea's DP partner, contributing to the successful development of MAR002.

"We are pleased to have successfully completed this comprehensive project with Marea Therapeutics, delivering on our commitment to high quality and accelerated timelines," said Dr. Alfred Merz, Chief Executive Officer of ProBioGen. "This collaboration exemplifies our customer-centric approach and our ability to support biotech companies with innovative and flexible solutions, enabling a sprint to IND to meet their challenging timelines. We look forward to seeing the continued progress of MAR002."

Mark Joing, Chief Development Operations Officer of Marea, added: "Working with ProBioGen has been a highly rewarding experience. Their technical expertise, dedication to quality, and reliability, as well as industry-standard-exceeding results reaffirmed ProBioGen as the right partner for Marea. MAR002 holds promise as a first-in-class treatment for acromegaly, a life-shortening disease often with serious complications. We appreciate ProBioGen's support throughout the process and look forward to continuing our collaboration as we advance to the next stages."

The partnership between ProBioGen and Marea Therapeutics has successfully laid the foundation for MAR002's next development stages. With key CMC milestones achieved, Marea is well-positioned to advance the candidate further toward clinical and commercial readiness. ProBioGen's services were performed on a fee-for-service basis, with no associated royalties. Further financial details remain undisclosed.